Trial Information

Summary: Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma

Sponsored by: GlaxoSmithKline

Purpose: This study is being conducted to characterize the safety/tolerability of pazopanib and lapatinib when administered in combination with enzyme-inducing anticonvulsants in patients with recurrent Grade III or IV malignant gliomas.

Official Title: Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination With Lapatinib in Adult Patients With Relapsed Malignant Glioma

Expected Total Enrollment: 105

Study start: August 2006

Eligibility

Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both

Criteria

Inclusion criteria:

• On enzyme inducing anticonvulsants.
• Diagnosis of anaplastic astrocytoma, anaplastic oligodendroglioma, mixed anaplastic oligoastrocytoma, glioblastoma multiforme, or gliosarcoma.
• Tumor tissue must be analyzed prior to enrollment.
• Normal bone marrow, liver, kidney and heart function.

Exclusion criteria:

• Severe or uncontrolled medical disease.
• History of heart attack, heart failure, prolonged QTc, blood clot, or excessive bleeding.
• Require COUMADIN therapy.
• Taking specifically prohibited medications.

For more information,

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:29:52 AM